{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:08:19Z","timestamp":1788174499617,"version":"build-2803163510"},"reference-count":53,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"Importance<\/jats:title>The current standard-of-care salvage therapy in relapsed\/refractory classic Hodgkin lymphoma (cHL) includes consolidation high-dose chemotherapy (HDCT)\/autologous stem cell transplant (aSCT).<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate whether presalvage risk factors and fludeoxyglucose-18 (FDG) positron emission tomography (PET) response to reinduction chemotherapy can guide escalation or de-escalation between HDCT\/aSCT or transplant-free consolidation with radiotherapy to minimize toxic effects while maintaining high cure rates.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>EuroNet-PHL-R1 was a nonrandomized clinical trial that enrolled patients younger than 18 years with first relapsed\/refractory cHL across 68 sites in 13 countries in Europe between January 2007 and January 2013. Data were analyzed between September 2022 and July 2024.<\/jats:p><\/jats:sec>Intervention<\/jats:title>Reinduction chemotherapy consisted of alternating IEP (ifosfamide, etoposide, prednisolone) and ABVD (adriamycin, bleomycin, vinblastine, dacarbazine). Patients with low-risk disease (late relapse after 2 cycles of first-line chemotherapy and any relapse with an adequate response after 1 IEP\/ABVD defined as complete metabolic response on FDG-PET and at least 50% volume reduction) received a second IEP\/ABVD cycle and radiotherapy (RT) to all sites involved at relapse. Patients with high-risk disease (all primary progressions and relapses with inadequate response after 1 IEP\/ABVD cycle) received a second IEP\/ABVD cycle plus HDCT\/aSCT with or without RT.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary end point was 5-year event-free survival. Secondary end points were overall survival (OS) and progression-free survival (PFS). PFS was identical to event-free survival because no secondary cancers were observed. PFS data alone are presented for simplicity.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 118 patients analyzed, 58 (49.2%) were female, and the median (IQR) age was 16.3 (14.5-17.6) years. The median (IQR) follow-up was 67.5 (58.5-77.0) months. The overall 5-year PFS was 71.3% (95% CI, 63.5%-80.1%), and OS was 82.7% (95% CI, 75.8%-90.1%). For patients in the low-risk group (n\u2009=\u200959), 41 received nontransplant salvage with a 5-year PFS of 89.7% (95% CI, 80.7%-99.8%) and OS of 97.4% (95% CI, 92.6%-100%). In contrast, 18 received HDCT\/aSCT off protocol, with a 5-year PFS of 88.9% (95% CI, 75.5%-100%) and OS of 100%. All 59 patients with high-risk disease received HDCT\/aSCT (and 23 received post-HDCT\/aSCT RT) with a 5-year PFS of 53.3% (95% CI, 41.8%-67.9%) and OS of 66.5% (95% CI, 54.9%-80.5%).<\/jats:p><\/jats:sec>Conclusion and Relevance<\/jats:title>In this nonrandomized clinical trial, FDG-PET response-guided salvage in relapsed cHL may identify patients in whom transplant-free salvage achieves excellent outcomes. HDCT\/aSCT may be reserved for primary progression and relapsed cHL with inadequate response.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT00433459<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2024.5636","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T16:01:05Z","timestamp":1735833665000},"page":"258","source":"Crossref","is-referenced-by-count":6,"title":["Transplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma"],"prefix":"10.1001","volume":"11","author":[{"given":"Stephen","family":"Daw","sequence":"first","affiliation":[{"name":"Pediatric Division, Children and Young People\u2019s Cancer Services, University College London Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Claviez","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University Hospital Magdeburg, Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Kurch","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich","family":"Stoevesandt","sequence":"additional","affiliation":[{"name":"Department of Radiology, University Hospital Halle (Saale), Halle (Saale), Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andishe","family":"Attarbaschi","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology and Oncology, St. Anna Children\u2019s Hospital, Medical University of Vienna, St Anna Children\u2019s Cancer Research Institute, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walentyna","family":"Balwierz","sequence":"additional","affiliation":[{"name":"Jagiellonian University Medical College, Institute of Pediatrics, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auke","family":"Beishuizen","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Cepelova","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology and Oncology, University Hospital Motol and 2nd Medical Faculty of Charles University, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ceppi","sequence":"additional","affiliation":[{"name":"Division of Pediatrics, Department of Woman-Mother-Child, Pediatric Hematology-Oncology Unit, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Fernandez-Teijeiro","sequence":"additional","affiliation":[{"name":"Universidad de Sevilla, Hospital Universitario Virgen Macarena, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Foss\u00e5","sequence":"additional","affiliation":[{"name":"Oslo University Hospital, Department of Oncology, and KG Jebsen Centre for B-cell malignancies, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Georgi","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Lyngsie","family":"Hjalgrim","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescents Medicine, Rigshospitalet Copenhagen, The Juliane Marie Centre, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Hraskova","sequence":"additional","affiliation":[{"name":"Disease and Comenius University Bratislava, Bratislava, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Leblanc","sequence":"additional","affiliation":[{"name":"H\u00f4pital Robert-Debr\u00e9, Service d\u2019H\u00e9matologie P\u00e9diatrique and Universit\u00e9 Paris-Cit\u00e9 Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Mascarin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, AYA Oncology and Pediatric Radiotherapy Unit, CRO Centro di Riferimento Oncologico, IRCCS, Aviano (PN), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Pears","sequence":"additional","affiliation":[{"name":"Children\u2019s Health Ireland, Crumlin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Landman-Parker","sequence":"additional","affiliation":[{"name":"Department of Paediatric Oncology and Haematology, H\u00f4pital Armand-Trousseau, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toma\u017e","family":"Prelog","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, University Children\u2019s Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Klapper","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Christian-Albrechts-Universit\u00e4t, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Ramsay","sequence":"additional","affiliation":[{"name":"Department of Cellular Pathology, University College Hospital London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regine","family":"Kluge","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Dieckmann","sequence":"additional","affiliation":[{"name":"Department of Radiooncology, Allgemeines Krankenhaus Wien, Medical University Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Pelz","sequence":"additional","affiliation":[{"name":"Department of Radiooncology, University Hospital Halle (Saale), Halle (Saale), Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Vordermark","sequence":"additional","affiliation":[{"name":"Department of Radiooncology, University Hospital Halle (Saale), Halle (Saale), Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"K\u00f6rholz","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology, Oncology and Immunodeficiency, University Hospital Justus-Liebig University Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hasenclever","sequence":"additional","affiliation":[{"name":"Institute for Medical Informatics, Statistics, and Epidemiology (IMISE), University of Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Mauz-K\u00f6rholz","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology, Oncology and Immunodeficiency, University Hospital Justus-Liebig University Giessen, Giessen, Germany"},{"name":"Medical Faculty of the Martin Luther University Halle-Wittenberg, Halle (Saale), Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"Suppl 6","key":"coi240073r1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30580","article-title":"Children\u2019s Oncology Group\u2019s 2023 blueprint for research: Hodgkin lymphoma.","volume":"70","author":"Castellino","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"coi240073r2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1470-2045(21)00470-8","article-title":"Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.","volume":"23","author":"Mauz-K\u00f6rholz","year":"2022","journal-title":"Lancet Oncol"},{"issue":"3","key":"coi240073r3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S1470-2045(23)00019-0","article-title":"Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study.","volume":"24","author":"Mauz-K\u00f6rholz","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"coi240073r4","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000329","article-title":"Risk and response adapted treatment guidelines for managing first relapsed and refractory classical Hodgkin lymphoma in children and young people\u2014recommendations from the EuroNet pediatric hodgkin lymphoma group.","volume":"4","author":"Daw","year":"2020","journal-title":"Hemasphere"},{"issue":"4","key":"coi240073r5","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/pbc.24851","article-title":"Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma.","volume":"61","author":"Harker-Murray","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"9323","key":"coi240073r6","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial.","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"issue":"8852","key":"coi240073r7","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial.","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"issue":"7","key":"coi240073r8","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"issue":"21","key":"coi240073r9","doi-asserted-by":"publisher","first-page":"6732","DOI":"10.1182\/bloodadvances.2023010404","article-title":"Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed\/refractory Hodgkin lymphoma.","volume":"7","author":"Driessen","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"coi240073r10","first-page":"8","article-title":"PET\/CT in the evaluation of relapsed or refractory Hodgkin lymphoma.","volume":"12","author":"Jauhari","year":"2016","journal-title":"Am J Hematol Oncol"},{"issue":"5","key":"coi240073r11","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00277-016-2619-9","article-title":"Prognostic value of pretransplant FDG-PET in refractory\/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis.","volume":"95","author":"Adams","year":"2016","journal-title":"Ann Hematol"},{"key":"coi240073r12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.929012","article-title":"Novel agents for relapsed and refractory classical Hodgkin lymphoma: a review.","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"issue":"10","key":"coi240073r13","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00761-022-01172-1","article-title":"Novel therapeutic approaches in relapsed or refractory Hodgkin lymphoma.","volume":"28","author":"Br\u00f6ckelmann","year":"2022","journal-title":"Onkologie"},{"issue":"4","key":"coi240073r14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.14740\/wjon1388","article-title":"Checkpoint inhibitors in relapsed\/refractory classical Hodgkin lymphoma.","volume":"12","author":"Tarekegn","year":"2021","journal-title":"World J Oncol"},{"issue":"10","key":"coi240073r15","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.3390\/cancers12102887","article-title":"Therapeutic updates for relapsed and refractory classical hodgkin lymphoma.","volume":"12","author":"Voorhees","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"8","key":"coi240073r16","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.3324\/haematol.2023.282731","article-title":"Can we cure relapsed\/refractory Hodgkin lymphoma without a stem cell transplant?","volume":"108","author":"Mei","year":"2023","journal-title":"Haematologica"},{"issue":"8","key":"coi240073r17","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.3324\/haematol.2022.282266","article-title":"Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial.","volume":"108","author":"Ding","year":"2023","journal-title":"Haematologica"},{"key":"coi240073r18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/blood-2020-142089","article-title":"Radiation-based approaches as an alternative to stem cell transplant for relapsed\/refractory classical Hodgkin lymphoma: a multicenter retrospective analysis.","volume":"136","author":"Larose","year":"2020","journal-title":"Blood"},{"issue":"1","key":"coi240073r19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1182\/hematology.2022000365","article-title":"Do all patients with primary refractory\/first relapse of HL need autologous stem cell transplant?","volume":"2022","author":"Moskowitz","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7","key":"coi240073r20","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.3390\/cancers14071738","article-title":"Autologous stem cell transplantation in Hodgkin lymphoma-latest advances in the era of novel therapies.","volume":"14","author":"Samara","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"coi240073r21","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1182\/hematology.2021000311","article-title":"How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents.","volume":"2021","author":"Driessen","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"18","key":"coi240073r22","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.1002\/cncr.25225","article-title":"Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients.","volume":"116","author":"Metzger","year":"2010","journal-title":"Cancer"},{"issue":"5","key":"coi240073r23","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/j.1365-2141.2012.09199.x","article-title":"Outcome of children and adolescents with recurrent\/refractory classical Hodgkin lymphoma, a study from the Soci\u00e9t\u00e9 Fran\u00e7aise de Lutte contre le Cancer des Enfants et des Adolescents (SFCE).","volume":"158","author":"Gorde-Grosjean","year":"2012","journal-title":"Br J Haematol"},{"issue":"4","key":"coi240073r24","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/bjh.12768","article-title":"Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma\u2014results of the UK HD3 relapse treatment strategy.","volume":"165","author":"Shankar","year":"2014","journal-title":"Br J Haematol"},{"issue":"25","key":"coi240073r25","doi-asserted-by":"publisher","first-page":"6181","DOI":"10.1200\/JCO.2005.07.930","article-title":"Salvage therapy of progressive and recurrent Hodgkin\u2019s disease: results from a multicenter study of the pediatric DAL\/GPOH-HD study group.","volume":"23","author":"Schellong","year":"2005","journal-title":"J Clin Oncol"},{"issue":"23","key":"coi240073r26","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.1200\/JCO.2009.26.9381","article-title":"Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin\u2019s lymphoma: the GPOH-HD-2002 study.","volume":"28","author":"Mauz-K\u00f6rholz","year":"2010","journal-title":"J Clin Oncol"},{"key":"coi240073r27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/10428194.2014.961011","article-title":"Feasibility of VECOPA: A dose-intensive chemotherapy regimen for children and adolescents with intermediate and advanced stage Hodgkin\u2019s lymphoma\u2014results of the GPOH-HD-2002\/VECOPA pilot trial.","volume":"10","author":"Mauz-K\u00f6rholz","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"coi240073r28","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1055\/s-0033-1354416","article-title":"The EuroNet paediatric hodgkin network\u2014modern imaging data management for real time central review in multicentre trials.","volume":"225","author":"Kurch","year":"2013","journal-title":"Klin Padiatr"},{"issue":"5","key":"coi240073r29","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"coi240073r30","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the first international workshop on interim-PET scan in lymphoma.","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"coi240073r31","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1182\/blood.V126.23.1978.1978","article-title":"Risk factors and a prognostic score for progression free survival after treatment with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory Hodgkin lymphoma (rrHL).","volume":"126","author":"Br\u00f6ckelmann","year":"2015","journal-title":"Blood"},{"issue":"6","key":"coi240073r32","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/annonc\/mdx072","article-title":"Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma.","volume":"28","author":"Br\u00f6ckelmann","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"coi240073r33","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1080\/10428194.2020.1732959","article-title":"Relapse or refractory Hodgkin lymphoma: determining risk of relapse or progression after autologous stem-cell transplantation.","volume":"61","author":"Bentolila","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"coi240073r34","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s12288-021-01463-4","article-title":"Clinico-epidemiological profile, prognostic factors and treatment outcome of refractory Hodgkin lymphoma.","volume":"38","author":"Zenzri","year":"2022","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"1","key":"coi240073r35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12880-023-00967-x","article-title":"Prognostic role of pretreatment 18F-FDG PET\/CT and hematological parameters in relapsed\/refractory Hodgkin lymphoma patients treated with immune checkpoint inhibitors and chemotherapy: a dual-center cohort study.","volume":"23","author":"Yang","year":"2023","journal-title":"BMC Med Imaging"},{"issue":"5","key":"coi240073r36","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/ajh.26500","article-title":"Risk stratification for relapsed\/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume.","volume":"97","author":"Yhim","year":"2022","journal-title":"Am J Hematol"},{"issue":"S3","key":"coi240073r37","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000975748.78092.4d","article-title":"PB2254: treatment outcome and prognostic factors in children and adolescents with relapses and refractory classic Hodgkin lymphoma.","volume":"7","author":"Ali","year":"2023","journal-title":"HemaSphere"},{"issue":"1","key":"coi240073r38","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1186\/s12885-020-07561-2","article-title":"Improving outcomes after autologous transplantation in relapsed\/refractory Hodgkin lymphoma: a European expert perspective.","volume":"20","author":"Sureda","year":"2020","journal-title":"BMC Cancer"},{"issue":"5","key":"coi240073r39","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jamaoncol.2018.6278","article-title":"Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation: a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT.","volume":"5","author":"Kanate","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"coi240073r40","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ijrobp.2017.05.007","article-title":"Role of consolidative radiation therapy after autologous hematopoietic cell transplantation for the treatment of relapsed or refractory Hodgkin lymphoma.","volume":"99","author":"Wilke","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"23","key":"coi240073r41","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1182\/blood.V126.23.3195.3195","article-title":"Consolidative radiation therapy following autologous transplantation in relapsed or refractory Hodgkin lymphoma.","volume":"126","author":"Jauhari","year":"2015","journal-title":"Blood"},{"issue":"4","key":"coi240073r42","doi-asserted-by":"publisher","first-page":"982","DOI":"10.3390\/cancers14040982","article-title":"Brentuximab vedotin and pembrolizumab combination in patients with relapsed\/refractory Hodgkin lymphoma: a single-centre retrospective analysis.","volume":"14","author":"Massaro","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"coi240073r43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/bmt.2017.196","article-title":"Post-autologous transplant maintenance therapies in lymphoma: current state and future directions.","volume":"53","author":"Riedell","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"coi240073r44","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.3324\/haematol.2023.282780","article-title":"Effect of cumulative dose of brentuximab vedotin maintenance in relapsed\/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes.","volume":"108","author":"Wagner","year":"2023","journal-title":"Haematologica"},{"issue":"22","key":"coi240073r45","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1182\/blood.V128.22.5357.5357","article-title":"Post transplant brentuximab maintenance appears more effective than post transplant salvage brentuximab for relapsed\/refractory Hogkin\u2019s lymphoma.","volume":"128","author":"Chidiac","year":"2016","journal-title":"Blood"},{"issue":"22","key":"coi240073r46","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1182\/blood.2022018827","article-title":"Improved outcomes for relapsed\/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents.","volume":"141","author":"Spinner","year":"2023","journal-title":"Blood"},{"issue":"13","key":"coi240073r47","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/bloodadvances.2022009323","article-title":"Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed\/refractory Hodgkin lymphoma.","volume":"7","author":"Forlenza","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"coi240073r48","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.ijrobp.2018.01.011","article-title":"The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: guidelines from the International Lymphoma Radiation Oncology Group.","volume":"100","author":"Constine","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"coi240073r49","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ijrobp.2023.04.022","article-title":"Radiation therapy use in refractory and relapsed adolescent and young adult Hodgkin lymphoma: a report from the Children\u2019s Oncology Group.","volume":"117","author":"Mailhot Vega","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"coi240073r50","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1182\/blood-2019-122716","article-title":"Impact of Post-transplant consolidative radiotherapy in patients with relapsed or refractory classical Hodgkin lymphoma and a PET-CT based predictive model for relapse.","volume":"134","author":"Chin","year":"2019","journal-title":"Blood"},{"issue":"3","key":"coi240073r51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.07.954","article-title":"Radiation therapy (RT)-based salvage therapy for classical Hodgkin lymphoma (cHL).","volume":"111","author":"Manjunath","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"coi240073r52","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG).","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"coi240073r53","doi-asserted-by":"publisher","first-page":"338","DOI":"10.2967\/jnumed.120.247924","article-title":"Comparison of interim PET response to second-line versus first-line treatment in classic Hodgkin lymphoma: contribution to the development of response criteria for relapsed or progressive disease.","volume":"62","author":"Kluge","year":"2021","journal-title":"J Nucl Med"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2828594\/jamaoncology_daw_2025_oi_240073_1741392604.87328.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T21:25:39Z","timestamp":1742505939000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2828594"}},"subtitle":["The EuroNet-PHL-R1 Phase 3 Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.5636","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,1]]}}}